Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 10-21 years.~2. Sex: male and female subjects will be enrolled.~3. Tanner stage: I-V.~4. T1D duration of \<3 months (i.e., from first insulin injection) to ensure the inclusion of patients in PCR.~5. Presence of at least one diabetes-associated autoantibody.~6. Normal-weight, overweight-, and obese subjects with T1D~7. Fasting serum C-peptide level of \>0.1 nmol/L (0.3 ng/mL)1; or 2-hour post-meal stimulated C-peptide level of 0.2 nmol/L (≥0.6 ng/mL).~Exclusion Criteria:~1. Subjects on weight altering medications, such as orlistat.~2. Subjects with eating disorders~3. Subjects on medications other than insulin that can affect blood glucose level.~4. Subjects with 25-hydroxyvitamin D \[25(OH)D\] levels of \>70 ng/mL, as this may lead to vitamin D toxicity in the study subjects.~5. Subjects with systemic diseases other than T1D.~6. Subjects with recurrent diabetic ketoacidosis (\>2 episodes since the diagnosis of T1D or in the preceding 3 months); or \>2 episodes of severe hypoglycemia in the preceding 3 mo.~7. Pregnant or breast-feeding female subjects.~8. The receipt of any investigational drug within 6 months prior to this trial.~9. Active malignant neoplasm.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol (Type: EXPERIMENTAL): Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D

Based on this trial design, predict the completion outcome and termination type (if applicable).